AVRO - AVROBIO: Promise In Fabry Disease
Capital Structure
Price per share: ~$21 | Market capitalization: ~$650M
Cash and cash equivalents: $206M | Debt: NA
Cash burn: ~$20M/quarter | Cash runway: into 2021
Commercial assets: 0 | Phase 3: 0 | Phase 2: 1 | Phase 1: 2
Introduction
AVROBIO (AVRO) is a phase 2 biotechnology company developing lentiviral-based gene therapies (via the HIV) for Lysosomal Storage Disorders (Fabry, Gaucher, Cystinosis).
Source: AVROBIO
Compared to other gene therapies, lentiviral-based ones are theorized to benefit from a broad host range, low cytotoxicity, and long-term expression. These characteristics make lentiviral-based gene therapies